Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Objectives Body mass index (BMI) confers a higher risk of colorectal cancer (CRC) and may influence cancer diagnostic ...

Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts SessionCompany to ...

Deb Hipp is a freelance health and medical writer and editor who lives in Kansas City, Missouri. She is a former investigative reporter with more than 25 years of experience as a journalist and writer ...

A simple blood test can reveal the geographic relationships among healthy cells surrounding a cancerous tumor, researchers at ...

Andrew Bloomenthal has 20+ years of editorial experience as a financial journalist and as a financial services marketing writer. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Objectives To identify whether patients with arrhythmia, heart failure or ischaemic heart disease presenting with anxiety ...

Q1 2026 revenue of €197 million for YORVIPATH and €44 million for SKYTROFA - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL enrollments ...

Facebook Pages provide a way for consumers to connect to your business. The key to getting visits to the Page is building a community of readers who have a reason to return. Using subgroups helps ...

Background Hepatocellular carcinoma (HCC), one of the most prevalent cancers worldwide, has a high mortality owing to ...